Nilofer S. Azad
#128,546
Most Influential Person Now
American oncologist and physician-scientist
Nilofer S. Azad's AcademicInfluence.com Rankings
Nilofer S. Azadphilosophy Degrees
Philosophy
#11183
World Rank
#15367
Historical Rank
#2117
USA Rank
Logic
#7994
World Rank
#9948
Historical Rank
#1273
USA Rank
Download Badge
Philosophy
Nilofer S. Azad's Degrees
- Doctorate Medicine Harvard University
Why Is Nilofer S. Azad Influential?
(Suggest an Edit or Addition)According to Wikipedia, Nilofer Saba Azad is an American oncologist and physician-scientist specialized in gastrointestinal, colorectal, cholangiocarcinoma, and pancreaticobiliary cancers. She is a professor at the Johns Hopkins School of Medicine and oversees clinical trials at the Sidney Kimmel Comprehensive Cancer Center.
Nilofer S. Azad's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade (2017) (4313)
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. (2015) (3718)
- PD-1 blockade in tumors with mismatch repair deficiency. (2015) (2914)
- Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study (2020) (1264)
- Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers (2014) (344)
- Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. (2008) (322)
- The future of epigenetic therapy in solid tumours—lessons from the past (2013) (295)
- PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. (2019) (282)
- Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. (2014) (171)
- Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases (2013) (161)
- Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease (2018) (155)
- Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors (2014) (138)
- Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. (2019) (128)
- Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy (2009) (125)
- Single-Center Phase II Trial of Transarterial Chemoembolization With Drug-Eluting Beads for Patients With Unresectable Hepatocellular Carcinoma: Initial Experience in the United States (2009) (125)
- Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival (2019) (122)
- The DNA Damaging Revolution: PARP Inhibitors and Beyond. (2019) (115)
- Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future. (2020) (112)
- Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours (2016) (109)
- An analysis of genetic heterogeneity in untreated cancers (2019) (107)
- Keratoacanthomas associated with sorafenib therapy. (2007) (102)
- Programmed death-1 blockade in mismatch repair deficient colorectal cancer. (2016) (98)
- Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: Results from the cholangiocarcinoma dose escalation and expansion cohorts. (2017) (94)
- Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. (2021) (91)
- Colorectal Cancer in the Young: Epidemiology, Prevention, Management. (2020) (86)
- Proteomics in Clinical Trials and Practice (2006) (82)
- Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study. (2019) (75)
- PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers. (2016) (71)
- Mutational profiling of colorectal cancers with microsatellite instability (2015) (71)
- A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis (2014) (68)
- Surgery for colorectal liver metastases: The evolution of determining prognosis. (2013) (67)
- A randomized pilot trial of a telephone‐based couples intervention for physical intimacy and sexual concerns in colorectal cancer (2014) (62)
- Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand Up 2 cancer study (2017) (61)
- Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity (2010) (60)
- American College of Radiology ACR Appropriateness Criteria (2015) (56)
- Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer (2017) (56)
- Epigenetic therapy for solid tumors: from bench science to clinical trials. (2015) (52)
- Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis (2020) (51)
- Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers (2015) (51)
- Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models (2015) (50)
- The role of epigenetic therapies in colorectal cancer. (2018) (50)
- Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab. (2006) (47)
- Proteomics as a Tool for Biomarker Discovery (2007) (47)
- Intensity-Modulated Radiation Therapy for Rectal Carcinoma Can Reduce Treatment Breaks and Emergency Department Visits (2012) (45)
- Abstract PL04-05: The first reported results of AG-120, a first-in-class, potent inhibitor of the IDH1 mutant protein, in a Phase I study of patients with advanced IDH1-mutant solid tumors, including gliomas (2015) (42)
- A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers. (2016) (40)
- A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours (2014) (39)
- Lack of reliability of CA125 response criteria with anti‐VEGF molecularly targeted therapy (2008) (36)
- A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in Metastatic Colorectal Cancer Patients Previously Exposed to Irinotecan (2018) (34)
- Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer (2018) (34)
- A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer (2019) (34)
- The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma (2017) (32)
- Immune checkpoint inhibitor therapy in biliary tract cancer (cholangiocarcinoma). (2020) (32)
- A phase 1 study of ABT-806 in subjects with advanced solid tumors (2015) (31)
- Programmed death-1 blockade in mismatch repair deficient cancer independent of tumor histology. (2016) (30)
- The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma (2018) (29)
- ACR Appropriateness Criteria® Resectable Rectal Cancer (2012) (28)
- Feasibility and safety of sequential research‐related tumor core biopsies in clinical trials (2013) (28)
- Dual targeting of vascular endothelial growth factor (VEGF) with sorafenib and bevacizumab: Clinical and translational results (2007) (27)
- Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. (2022) (27)
- Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab (2015) (26)
- CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer (2014) (22)
- Clinicopathologic Comparison of High-Dose-Rate Endorectal Brachytherapy versus Conventional Chemoradiotherapy in the Neoadjuvant Setting for Resectable Stages II and III Low Rectal Cancer (2012) (21)
- DNA-intercalators Causing Rapid Re-expression of Methylated and Silenced Genes in Cancer Cells (2013) (20)
- Long‐term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer (2017) (20)
- Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers. (2021) (20)
- MEK inhibition suppresses B regulatory cells and augments anti-tumor immunity (2019) (19)
- Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer (2016) (19)
- Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer (2013) (19)
- Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma (2020) (18)
- Ovarian cancer in the proteomics era (2008) (17)
- The ongoing evolution of proteomics in malignancy. (2007) (17)
- Analysis of fiducials implanted during EUS for patients with localized rectal cancer receiving high-dose rate endorectal brachytherapy. (2015) (17)
- ENCORE 601: A phase 2 study of entinostat in combination with pembrolizumab in patients with microsatellite stable metastatic colorectal cancer. (2018) (16)
- Cost-utility of colorectal cancer screening at 40 years old for average-risk patients. (2020) (16)
- Neoantigen-based EpiGVAX vaccine initiates antitumor immunity in colorectal cancer. (2020) (15)
- Phase I/II study of regorafenib (rego) and pembrolizumab (pembro) in refractory microsatellite stable colorectal cancer (MSSCRC). (2022) (15)
- A Phase I Study of Dinaciclib in Combination With MK‐2206 in Patients With Advanced Pancreatic Cancer (2020) (15)
- Reporting of preclinical tumor-graft cancer therapeutic studies (2012) (15)
- A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers (2019) (15)
- A phase 1 trial of the oral DNA methyltransferase inhibitor CC‐486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors (2019) (14)
- Translational Predictive Biomarker Analysis of the Phase 1b Sorafenib and Bevacizumab Study Expansion Cohort* (2013) (13)
- Sequential short-course radiation therapy and chemotherapy in the neoadjuvant treatment of rectal adenocarcinoma (2019) (13)
- Abstract CT043: A multicenter randomized phase 2 trial of atezolizumab as monotherapy or in combination with cobimetinib in biliary tract cancers (BTCs): A NCI Experimental Therapeutics Clinical Trials Network (ETCTN) study (2020) (13)
- A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer (2016) (13)
- Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer (2018) (11)
- ACR Appropriateness Criteria® Borderline and Unresectable Pancreas Cancer. (2016) (10)
- A Palliative Care Intervention for Patients on Phase 1 Studies. (2020) (10)
- Abstract 2506: A phase 1 study of ABT-806, a humanized recombinant anti-EGFR monoclonal antibody, in patients with advanced solid tumors (2012) (9)
- A Phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors (2009) (9)
- Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017 (2020) (9)
- ACR Appropriateness Criteria®-Anal Cancer. (2014) (8)
- Protein synthesis inhibitor omacetaxine is effective against hepatocellular carcinoma (2021) (8)
- A robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of 5-azacytidine. (2016) (8)
- Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures (2022) (8)
- A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint (2021) (7)
- Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017 (2022) (7)
- Phase 2 study of programmed death-1 antibody (anti-PD-1, MK-3475) in patients with microsatellite unstable (MSI) tumors. (2014) (7)
- A phase I safety study of NPC-1C: A novel, therapeutic antibody to treat pancreas and colorectal cancers. (2012) (7)
- ACR Appropriateness Criteria Radiologic Management of Hepatic Malignancy. (2016) (7)
- A phase I study of LY3410738, a first-in-class covalent inhibitor of mutant IDH1 in cholangiocarcinoma and other advanced solid tumors. (2021) (7)
- First-in-human study of AMG 900, an oral pan-Aurora kinase inhibitor, in adult patients (pts) with advanced solid tumors. (2012) (7)
- Current Surgical Management Strategies for Colorectal Cancer Liver Metastases (2022) (7)
- Spirituality in cancer patients on phase 1 clinical trials (2020) (7)
- A phase II study of intermittent sorafenib with bevacizumab (B) in B-naive and prior B-exposed epithelial ovarian cancer (EOC) patients. (2014) (6)
- Racial disparities and colorectal cancer survival in older adults with and without diabetes mellitus (2014) (6)
- Executive Summary of the ARS Appropriate Use Criteria for Local Excision in Rectal Cancer. (2019) (5)
- Correlative studies of a phase I trial of combination anti-vascular endothelial growth factor (VEGF) therapy with sorafenib and bevacizumab (2008) (5)
- Entinostat in combination with nivolumab for patients with advanced cholangiocarcinoma and pancreatic adenocarcinoma. (2018) (5)
- A phase II study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair–proficient (MMR-p) advanced colorectal cancer. (2019) (5)
- A phase I/IIA safety study of NPC-1C: A novel, therapeutic antibody to treat pancreas and colorectal cancers. (2012) (4)
- Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer (2020) (4)
- Phase 1, open-label, adaptive biomarker trial that informs the evolution of combination immuno-oncology (IO) therapies (ADVISE), a precision IO approach to personalized medicine. (2018) (4)
- Epigenetic priming prior to pembrolizumab in mismatch repair-proficient advanced colorectal cancer. (2019) (4)
- Primary anorectal lymphoma presenting as a perianal abscess in an HIV-positive male. (2002) (4)
- Context-Dependent Immunomodulatory Effects of MEK Inhibition Are Enhanced with T-cell Agonist Therapy (2021) (4)
- NPC-1C: A novel, therapeutic antibody to treat pancreas and colorectal cancers. (2011) (4)
- Targeting the epigenome of pancreatic cancer for therapy: challenges and opportunities (2019) (4)
- Equity and diversity in academic medicine: a perspective from the JCI editors. (2019) (4)
- Relationship between lymphopenia and objective response rate with programmed death-1 (PD-1) inhibitor therapy: A single-center retrospective analysis. (2017) (4)
- Pazopanib (P) and trametinib (T) in advanced cholangiocarcinoma (CC): A phase Ib study. (2015) (3)
- Relationship of lymphocyte and eosinophil counts and immune-related adverse events in recipients of programmed death-1 (PD-1) inhibitor therapy: A single-center retrospective analysis. (2017) (3)
- A randomized trial of a palliative care intervention for patients on phase I studies. (2020) (3)
- Executive Summary of the ARS Appropriate Use Criteria for Treatment of Anal Cancer. (2019) (3)
- Precision Cancer Trials With Immunomodulatory Agents (2019) (3)
- A phase I/II multicenter study of the chimeric monoclonal antibody NEO102 (NPC-1C) in adults with refractory pancreatic (PC) and colorectal cancer (CC). (2015) (3)
- A phase Ib study of guadecitabine and durvalumab in patients with advanced hepatocellular carcinoma, pancreatic adenocarcinoma, and biliary cancers. (2022) (3)
- Tumor mutational burden (TMB) and response rates to immune checkpoint inhibitors (ICIs) targeting PD-1, CTLA-4, and combination. (2019) (3)
- A phase Ib/IIa study of NEO-102: A therapeutic antibody to treat pancreatic and colorectal cancers. (2014) (3)
- Development, Practice Patterns, and Early Clinical Outcomes of a Multidisciplinary Liver Cancer Clinic (2021) (3)
- A first-in-human phase I study of MORAb-004 (MOR4), a humanized monoclonal antibody recognizing TEM-1 (endosialin), in patients with solid tumors. (2011) (3)
- Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection (2021) (3)
- Readmission Adversely Affects Survival in Surgical Rectal Cancer Patients (2019) (3)
- ACR Appropriateness Criteria® rectal cancer: metastatic disease at presentation. (2014) (3)
- Phase II study of nivolumab and relatlimab in advanced mismatch repair deficient (dMMR) cancers resistant to prior PD-(L)1 inhibition. (2020) (3)
- ACR Appropriateness Criteria® Resectable Pancreatic Cancer. (2017) (3)
- A phase I study determining the safety and tolerability of combination therapy with pazopanib, a VEGFR/PDGFR/raf inhibitor, and GSK1120212, a MEK inhibitor, in advanced solid tumors enriched with patients with advanced differentiated thyroid cancer. (2012) (3)
- A phase I, single-institution open-label, dose-escalation trial with an expansion cohort evaluating the safety and tolerability of AZD6244 and IMC-A12 in subjects with advanced solid malignancies. (2011) (3)
- A phase I/II study of PI3Kinase inhibition with copanlisib combined with the anti-PD-1 antibody nivolumab in relapsed/refractory solid tumors with expansions in MSS colorectal cancer. (2020) (3)
- Translational proof of mechanism (PoM) for sorafenib with bevacizumab: Endpoint analysis and clinical activity. (2009) (3)
- Abstract CT242: SNDX-6352-0502: A phase 1, open-label, dose escalation trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic activity of SNDX-6352 in combination with durvalumab in patients with unresectable, recurrent, locally-advanced, or metastatic solid tumors (2020) (3)
- Multimodal profiling of biliary tract cancers to detect potentially actionable biomarkers and differences in immune signatures between subtypes. (2021) (2)
- A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies (2022) (2)
- RESECTABLE PANCREATIC CANCER (2016) (2)
- ACR Appropriateness Criteria® Local Excision in Early Stage Rectal Cancer (2015) (2)
- Ensituximab (E) in patients (pts) with refractory metastatic colorectal cancer (mCRC): Results of a phase I/II clinical trial. (2017) (2)
- Incidence and prognostic impact of KRAS and BRAF mutations in patients undergoing liver surgery for colorectal metastases. (2012) (2)
- A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype (2021) (2)
- Abstract CT017: A phase I study of guadecitabine (GUA) combined with irinotecan (IRI) in previously treated metastatic colorectal cancer (mCRC) patients (2016) (2)
- A phase II study of combination epigenetic therapy in metastatic colorectal cancer (mCRC): A phase II consortium (P2C)/Stand Up 2 Cancer (SU2C) study. (2013) (2)
- Changes in circulating lymphocyte counts and tumor-infiltrating lymphocyte subpopulations among patients receiving endorectal brachytherapy for rectal adenocarcinoma. (2014) (2)
- Multiclonal colorectal cancers with divergent histomorphological features and RAS mutations: one cancer or separate cancers? (2020) (2)
- The utility of molecular testing in colorectal cancer: the promise needs progress. (2014) (2)
- ACR Appropriateness Criteria® Resectable Stomach Cancer. (2015) (2)
- Nonoperative Management Following Complete Response in Rectal Cancer After Short-course Radiation Therapy and Consolidation Chemotherapy (2022) (1)
- AB049. P-17. A phase II study of HDAC inhibition to sensitize to immunotherapy in advanced cholangiocarcinoma (2019) (1)
- Real-World Analysis of Treatment Patterns, Healthcare Utilization, Costs, and Mortality Among People with Biliary Tract Cancers in the USA (2022) (1)
- A phase II multicenter study of the chimeric monoclonal antibody NEO102 (N) in adults with refractory colorectal cancer (CC). (2015) (1)
- ACR Appropriateness Criteria® rectal cancer (2014) (1)
- Abstract B263: Combined inhibition of cyclin-dependent kinases (Dinaciclib) and AKT (MK-2206) or ERK (SCH772984) dramatically blocks pancreatic tumor growth and metastases in patient-derived orthotopic xenograft models. (2013) (1)
- Sequential Short-Course Radiation Therapy and Chemotherapy in the Neoadjuvant Treatment of Rectal Cancer (2019) (1)
- An analysis of genetic heterogeneity in untreated cancers (2019) (1)
- First report of the correlation of PET Response Criteria in Solid Tumors (PERCIST) criteria and pathologic change in patients with rectal cancer treated with neoadjuvant radiation. (2013) (1)
- Novel score to predict outcome in resected pancreatic neuroendocrine tumors (pNET). (2015) (1)
- Early results of intratumoral INT230-6 alone or in combination with ipilimumab in subjects with advanced sarcomas. (2021) (1)
- 711 Interim results of a phase 2 study of nivolumab and relatlimab in advanced mismatch repair deficient (dMMR) cancers resistant to prior PD-(L)1 inhibition (2022) (1)
- A phase II trial of PD-1 inhibition with INCMGA00012 in patients with previously treated unresectable or metastatic adenosquamous pancreatic cancer. (2020) (1)
- Phase I study combining the aurora kinase A (AURKA) inhibitor alisertib (Ali) with mFOLFOX in gastrointestinal (GI) cancer. (2017) (1)
- Abstract A053: Prevalence of mismatch repair deficiency (dMMR) in the NCI Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131) population (2018) (1)
- Application of Serum and Tissue Proteomics to Understand and Detect Solid Tumors (2008) (1)
- Tolerance of full-dose sorafenib (S) combined with irinotecan (I; weekly, two on, one off) and cetuximab (C) in previously treated patients with advanced colorectal cancer (CRC). (2011) (1)
- A phase I study to evaluate safety, tolerability, pharmacokinetics and activity of oraxol in patients (pts) with advanced malignancies. (2018) (1)
- Impact of the COVID-19 Pandemic on Liver Cancer Staging at a Multidisciplinary Liver Cancer Clinic (2022) (1)
- A first-in-human phase I study of MORAb-004 (M4), a humanized monoclonal antibody recognizing endosialin (TEM-1), in patients with solid tumors. (2012) (1)
- Academic Cancer Center Phase I Program Development (2017) (1)
- A phase II trial of low-dose multiagent chemotherapy with gemcitabine, docetaxel, capecitabine, and cisplatin (GTX-C) in patients with metastatic pancreatic cancer. (2014) (1)
- A phase I trial of oral 5-azacitidine in combination with romidepsin in advanced solid tumors with an expansion cohort in virally mediated cancers and liposarcoma. (2015) (1)
- RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. (2022) (1)
- Correction: A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET) (2017) (1)
- 601 A First-in-human, Phase 1 Clinical Study of the Safety, Tolerability and Pharmacokinetics (PK) of G-202, a Thapsigargin-based PSMA-activated Prodrug, in Patients with Advanced Solid Tumors (2012) (1)
- Abstract CT149: SNDX-6352-0502 - A phase 1, open-label, dose escalation trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic activity of SNDX-6352 monotherapy in patients with unresectable, recurrent, locally-advanced, or metastatic solid tumors (2020) (1)
- A phase I study of investigational agent SGI-110 combined with irinotecan in previously treated metastatic colorectal cancer patients. (2015) (1)
- Prospective assessment of symptoms and quality of life in localized rectal cancer patients receiving chemoradiotherapy. (2011) (1)
- Abstract LB-161: A phase I safety study of NPC-1C, a novel, therapeutic antibody to treat pancreas and colorectal cancers. (2013) (1)
- Corrigendum: Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer (Annals of Oncology (2018) 29 (139-144) DOI: 10.1093/annonc/mdx688) (2019) (1)
- Pharmacodynamic, safety, and efficacy results of a phase I/II trial of intratumoral INT230-6 alone (IT-01) or in combination with pembrolizumab (PEM) (Keynote A10) in patients with advanced solid tumors. (2020) (1)
- Clinical Predictors of Early Trial Discontinuation for Patients Participating in Phase I Clinical Trials in Oncology (2021) (1)
- Neoadjuvant High Dose Endorectal Brachytherapy for Rectal Adenocarcinoma; Updated Preliminary Outcome Study (2013) (0)
- Morphological response of tumor histology in a phase I trial of sorafenib and bevacizumab (2008) (0)
- Effect of VERU-111, a novel oral inhibitor of α and β tubulin, on tumor growth in the human castration-resistant prostate cancer model 22Rv1. (2018) (0)
- Abstract 652:GPX3promoter hypermethylation predicts platinum sensitivity in colorectal cancer cells. (2013) (0)
- Changes in FDG-PET SUV correlate with voxel absorbed dose in HDR brachytherapy of rectal cancer (2012) (0)
- Molecular Targets in Ovarian Cancer and Endometrial Cancer (2008) (0)
- Clinical and molecular features of adenosquamous pancreatic cancer (ASQ): A distinct histological subtype. (2021) (0)
- RECURRENT RECTAL CANCER (2014) (0)
- Diagnosis and Definition of Locally Advanced and Borderline Pancreas Cancer (2017) (0)
- Phase I Trial of Intravenous Mistletoe Extract in Advanced Cancer (2023) (0)
- Combined MEK/PD-L1 inhibition alters peripheral cytokines and lymphocyte populations correlating with improved clinical outcomes in advanced biliary tract cancer. (2022) (0)
- Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. (2019) (0)
- Abstract I13: Modulating the immune response with epigenetic agents (2019) (0)
- A phase I study of a mutant KRAS-targeted long peptide vaccine in patients at high risk of developing pancreatic cancer. (2023) (0)
- 411 Novel intratumoral agent, INT230–6 induces cancer cell death, increases tumor infiltrates and results in durable benefit alone or in combination with pembrolizumab in refractory patients (2020) (0)
- ARS Appropriate Use Criteria ANAL CANCER EXPERT PANEL ON ANAL CANCER: (2019) (0)
- A phase I study of a mutant KRAS-targeted long peptide vaccine combined with ipilimumab/nivolumab in resected pancreatic cancer and MMR-proficient metastatic colorectal cancer. (2023) (0)
- 695 OMACETAXINE AS A POTENTIAL EFFECTIVE STRATEGY FOR HEPATOCELLULAR CARCINOMA (2020) (0)
- The effect of VERU-111, a novel oral inhibitor of α and β tubulin, on tumor growth in the human castration-resistant, AR-variant prostate cancer (PCa) model 22Rv1. (2019) (0)
- Feasibility and safety of sequential research-related tumor core biopsies in clinical trials with anti-angiogenic and targeted therapies. (2012) (0)
- A study of using epigenetic modulators to enhance response to pembrolizumab (MK-3475) in microsatellite stable advanced colorectal cancer (2023) (0)
- Radiographic predictors of response to endoluminal brachytherapy for the treatment of rectal cancer (2017) (0)
- Abstract 3971: MEK inhibitors limit inflammatory cytokine production and modulate the immune response in the setting of Cholangiocarcinoma. (2019) (0)
- Authors & Collaborators _ RAISE study (2015) (0)
- Borderline and Unresectable Pancreas Cancer (2016) (0)
- ETCTN 10476: A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without addition of cobimetinib in previously treated unresectable biliary tract cancer. (2023) (0)
- Anal Cancer (2013) (0)
- Abstract 1746: Epigenetic modulation of the tumor microenvironment enhances immune checkpoint efficacy in a murine model of pancreatic cancer (2018) (0)
- A new immunohistochemistry prognostic score (IPS) for recurrence and survival in pancreatic neuroendocrine tumors (PanNET). (2016) (0)
- Chemotherapy-induced diarrhea in older patients with colorectal cancer receiving fluoropyrimidines: A retrospective review. (2013) (0)
- Safety profile of INT230-6, a novel intratumoral (IT) formulation, during injections into a variety of refractory deep and superficial tumors with evidence of tumor regression and immune activation. (2019) (0)
- Response to McNamara's comment on "Cost-utility of colorectal cancer screening at age 40 years old for average-risk patients" by Azad et al. (2020) (0)
- A phase 2 study of NEO-102 (ensituximab), a novel chimeric monoclonal antibody, in adult patients (pts) with unresectable, metastatic colorectal cancer (mCRC). (2016) (0)
- 710 Safety and survival results from a phase 1/2 trial of intratumoral agent INT230–6 (cisplatin vinblastine) induces immunological cancer cell death alone or with pembrolizumab in patients with refractory, metastatic cancers (2022) (0)
- PO-404 VOXELIZED DOSE-RESPONSE STUDY IN HIGH DOSE RATE (HDR) 192IR BRACHYTHERAPY FOR RECTAL CANCER (2012) (0)
- Abstract 3993: Programmed cell death ligand-1 (PD-L1) and CD8 expression profiling identifies an immunologic subtype of pancreatic ductal adenocarcinomas with favorable survival (2019) (0)
- A first-in-human, phase 1 study of ASTX029, a dual-mechanism inhibitor of ERK1/2, in relapsed/refractory solid tumors. (2022) (0)
- A Novel Approach to Journal Club Designed to Immerse Trainees in a Peer-Review Process to Critically Evaluate Oncology Manuscripts (2016) (0)
- A phase II study of Guadecitabine (G) with Irinotecan (IRI) vs regorafenib or TAS-102 in metastatic colorectal cancer (mCRC) patients (pts) (2020) (0)
- Prospective Assessment of Quality of Life in Locally Advanced Rectal Cancer Patients Receiving Chemoradiotherapy (2011) (0)
- A randomized phase II trial of epigenetic therapy following adjuvant treatment in patients with resected pancreatic cancer and high risk for recurrence. (2015) (0)
- Abstract CT164: A Phase II clinical trial of GVAX pancreas vaccine (with Cyclophosphamide) in combination with Nivolumab and Stereotactic Body Radiation Therapy (SBRT) followed by definitive resection for patients with borderline resectable pancreatic adenocarcinoma (BR-PDAC) (2019) (0)
- Phase 1/2 trial evaluating intratumoral administration of INT230-6 alone and in combination with an anti-PD1 antibody for advanced malignancies. (2018) (0)
- A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence (2022) (0)
- Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers. (2023) (0)
- Sequential short-course radiation therapy and chemotherapy in the neoadjuvant treatment of rectal adenocarcinoma (2019) (0)
- Abstract B74: A Phase I trial of vertical inhibition of IGF signaling using IMC-A12, an IGF1-R inhibitor, and AZD6244, a MEK 1/2 inhibitor, in patients with advanced solid tumors. (2013) (0)
- A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint (2021) (0)
- Nivolumab in combination with dabrafenib and trametinib use in advanced cholangiocarcinoma with a BRAF V600E mutation and severe hepatic dysfunction: A case report and review of the literature (2023) (0)
- Abstract CT108: A first-in-human, Phase 1 study of ASTX029, a dual-mechanism inhibitor of ERK1/2, in relapsed/refractory solid tumors (2021) (0)
- Correction to: Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer (2018) (0)
- SU-E-J-270: Study of PET Response to HDR Brachytherapy of Rectal Cancer. (2014) (0)
- Abstract CT415: A Phase I/IIA multicenter clinical trial of the chimeric monoclonal antibody NEO102 (NPC-1C) in adults with refractory pancreatic and colorectal cancer (2014) (0)
- Chemoradiation-induced alteration of programmed death-ligand 1, CD8+ tumor-infiltrating lymphocytes and mucin expression in rectal cancer (2022) (0)
- A phase II therapeutic, open label, multi-center clinical trial of NPC-1C, a chimeric monoclonal antibody(mAb), in adults with chemotherapy refractory metastatic colorectal cancer (mCRC), initial results. (2016) (0)
- Reply to Lack of reliability of CA125 response criteria with anti‐VEGF molecularly targeted therapy (2008) (0)
- Chemoradiation-induced alteration of programmed death-ligand 1 and CD8+ tumor-infiltrating lymphocytes in rectal cancer. (2019) (0)
- Epigenetic priming prior to pembrolizumab in microsatellite-stable (MSS) advanced colorectal cancer. (2016) (0)
- A phase 1/2 study of intratumoral INT230-6 alone (IT-01) or in combination with pembrolizumab [KEYNOTE-A10] in adult subjects with locally advanced, unresectable and metastatic solid tumors refractory to therapy. (2021) (0)
- 501 Survival and immune response data from intratumoral INT230–6 alone (IT-01) and with pembrolizumab [KEYNOTE-A10] in subjects with locally advanced, unresectable and metastatic solid tumors (2021) (0)
- Voxelized Dose--FDG-PET Response in HDR Brachytherapy of Rectal Cancer. (2013) (0)
- Correction to "A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET)" [Oncotarget. 2016; 7(18): 25950-61]. doi: 10.18632/oncotarget.7436 (2017) (0)
- Abstract CT036: Safety and immunogenicity of a first-in-human mutant KRAS long peptide vaccine combined with ipilimumab/nivolumab in resected pancreatic cancer: Preliminary analysis from a phase I study (2023) (0)
- AB013. S3A-2. The future potential of immunotherapy in biliary tract cancer (2019) (0)
- W1755 Exploring Combination Epigenetic Therapy for the Treatment of Colorectal Cancer (2009) (0)
- Analysis of fiducials implanted during endoscopic ultrasound (EUS) for locally advanced rectal cancer patients receiving high-dose rate endorectal brachytherapy (Endo-HDR). (2014) (0)
- Thanks to authors and peer reviewers (2007) (0)
- A phase Ib/IIa study of NEO-102: A therapeutic antibody for the treatment of advanced pancreatic and colorectal cancer. (2014) (0)
- Abstract 3957: Optimized plasma collection procedures for liquid biopsy analyses in cancer (2016) (0)
- A phase I study of NPC-1C, a novel therapeutic antibody to treat pancreas and colorectal cancers. (2011) (0)
- AB095. P069. Identification of therapeutic genomic alterations by investigating cancer-related genes and microsatellite instability: road to precision medicine for pancreatic ductal adenocarcinoma (2018) (0)
- Solid Organ Transplantation Is Associated with an Increased Rate of Mismatch Repair Deficiency and PIK3CA Mutations in Colorectal Cancer (2022) (0)
- Abstract LB197: A pooled mutant KRAS peptide vaccine activates polyfunctional T cell responses in patients with resected pancreatic cancer (2023) (0)
- Abstract 2873: Evolution of immune cell composition and functionality as pancreatic intraepithelial neoplasia progresses to pancreatic ductal adenocarcinoma (2023) (0)
- Abstract 1686: Epigenetic modulation of the tumor microenvironment enhances vaccine induced T cell responses in a murine model of pancreatic cancer (2017) (0)
This paper list is powered by the following services:
Other Resources About Nilofer S. Azad
What Schools Are Affiliated With Nilofer S. Azad?
Nilofer S. Azad is affiliated with the following schools:
